Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 12/20 | 0.81 |
| ▸ | HTR2A | P28223 | 11/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.80 |
| ▸ | HTR2C | P28335 | 4/20 | 0.80 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.80 |
| ▸ | HRH1 | P35367 | 3/20 | 0.80 |
| ▸ | DRD3 | P35462 | 3/20 | 0.80 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.80 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.80 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.80 |
| ▸ | DRD1 | P21728 | 2/20 | 0.80 |
| ▸ | DRD4 | P21917 | 2/20 | 0.80 |
| ▸ | DRD5 | P21918 | 2/20 | 0.80 |
| ▸ | HTR1D | P28221 | 2/20 | 0.80 |
| ▸ | HTR1B | P28222 | 2/20 | 0.80 |
| ▸ | HTR7 | P34969 | 2/20 | 0.80 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.80 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.80 |
| ▸ | ACHE | P22303 | 3/20 | 0.73 |
| ▸ | HTR6 | P50406 | 3/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13929410 | 0.93 | DRD2 (0.80) | DRD2HTR2AKCNH2HTR2CADRA1A | |
| SCHEMBL15506067 | 0.92 | DRD2 (0.79) | DRD2HTR2AKCNH2HTR2CADRA1A | |
| SCHEMBL12428786 | 0.91 | DRD2 (0.78) | DRD2HTR2AKCNH2HTR2CADRA1A | |
| SCHEMBL8326588 | 0.91 | DRD2 (0.77) | DRD2HTR2AKCNH2HTR2CADRA1A | |
| SCHEMBL12415657 | 0.90 | DRD2 (0.76) | DRD2HTR2AKCNH2HTR2CADRA1A | |
| SCHEMBL19484373 | 0.90 | HTR2A (0.76) | DRD2HTR2AKCNH2HTR2CADRA1A | |
| SCHEMBL15489408 | 0.90 | HTR2A (0.76) | DRD2HTR2AKCNH2HTR2CADRA1A | |
| SCHEMBL801449 | 0.90 | DRD2 (0.85) | DRD2HTR2AKCNH2HTR2CADRA1A | |
| SCHEMBL7942739 | 0.89 | DRD2 (0.81) | DRD2HTR2AKCNH2HTR2CADRA1A | |
| SCHEMBL6883333 | 0.89 | HTR2A (0.75) | DRD2HTR2AKCNH2HTR2CADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0730594-B1 | 9-HYDROXY-PYRIDO [1,2-a]PYRIMIDIN-4-ONE ETHER DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 1999-09-08 | — | — | EP | claimed |
| EP-3556759-A1 | HAPTENS OF PALIPERIDONE | Janssen Pharmaceutica NV (BE) | 2019-10-23 | — | — | EP | disclosed |
| US-10370457-B2 | Antibodies to paliperidone haptens and use thereof | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-06 | — | — | US | disclosed |
| EP-2888258-B1 | HAPTENS OF PALIPERIDONE | JANSSEN PHARMACEUTICA NV (BE) | 2019-06-05 | — | — | EP | disclosed |
| US-20170298147-A1 | ANTIBODIES TO PALIPERIDONE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-19 | — | — | US | disclosed |
| US-20170129968-A1 | ANTIBODIES TO PALIPERIDONE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-11 | — | — | US | disclosed |
| US-20130053405-A1 | CARRIER LINKED PALIPERIDONE PRODRUGS | ASCENDIS PHARMA AS (DK) | 2013-02-28 | — | — | US | disclosed |
| WO-2010003702-A9 | SYNTHESIS OF PALIPERIDONE | SYNTHON B.V. (NL) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010003702-A1 | SYNTHESIS OF PALIPERIDONE | SYNTHON B.V. (NL) | 2010-01-14 | — | — | WO | disclosed |
| US-20090036470-A1 | PALIPERIDONE DERIVATIVES | SYNTHON BV (NL) | 2009-02-05 | — | — | US | disclosed |
| EP-0730594-B1 | 9-HYDROXY-PYRIDO [1,2-a]PYRIMIDIN-4-ONE ETHER DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 1999-09-08 | — | — | EP | disclosed |
| EP-0730594-A1 | NOVEL 9-HYDROXY-PYRIDO [1,2-a]PYRIMIDIN-4-ONE ETHER DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-09-11 | — | — | EP | disclosed |
| WO-1995014691-A1 | NOVEL 9-HYDROXY-PYRIDO[1,2-a]PYRIMIDIN-4-ONE ETHER DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370457-B2 | Antibodies to paliperidone haptens and use thereof | LY96, OPRL1, HTR3C | DRD2 380/4885HTR2A 33/4885KCNH2 2524/4885 |
| US-20170298147-A1 | ANTIBODIES TO PALIPERIDONE HAPTENS AND USE THEREOF | LY96, OPRL1, HTR3C | DRD2 380/4885HTR2A 33/4885KCNH2 2524/4885 |
| US-20130053405-A1 | CARRIER LINKED PALIPERIDONE PRODRUGS | ZDHHC20, HDAC10, SLC20A1 | DRD2 853/4885HTR2A 1444/4885KCNH2 898/4885 |
| US-20090036470-A1 | PALIPERIDONE DERIVATIVES | NPY1R, NPY4R, GLP1R | DRD2 440/4885HTR2A 501/4885KCNH2 1392/4885 |
| US-20170129968-A1 | ANTIBODIES TO PALIPERIDONE HAPTENS AND USE THEREOF | LY96, OPRL1, HTR3C | DRD2 380/4885HTR2A 33/4885KCNH2 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.